Chugai Pharmaceutical Co.

Japanese pharmaceutical company

TYO: 4519
Nikkei 225 component

IndustryPharmaceutical Industry, Business import, production and development of drugs for medical salesFoundedMarch 8, 1943; 81 years ago (1943-03-08)HeadquartersNihonbashi Mitsui Tower, Nihonbashi Muromachi 2-1-1, Chūō, Tokyo
On the registration Headquarter: Tokyo Kita (Tokyo)

Key people

Osamu Nagayama - Chairman and Tatsuro Kosaka - CEORevenue72.9 billion capital of 47 million yen. Standalone sales of 329.2 billion yen and 344.8 billion yen consolidated
(December 2007)ParentHoffmann-La Roche (61.62%)Websitewww.chugai-pharm.co.jp (in Japanese)

Chugai Pharmaceutical Co., Ltd. (中外製薬株式会社, Chūgai Seiyaku kabushiki gaisha) is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014.^[1] The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO.

History

Timeline

This is a timeline of important events of Chugai Pharmaceutical.^[2]

1925: Juzo Ueno founded Chugai Shinyaku Co. Ltd. and started importing and selling medicines
1927: Start of the first own production
1930: Salobrocanon, an analgesic (pain reliever ) and antipyretic, is launched
1937: Calcium bromide production begins
1943: Name changed to Chugai Pharmaceutical Co., Ltd. based in Tokyo
1944: Acquisition of Matsunaga Pharmaceutical Ltd. and construction of a plant in Matsunaga
1945: The headquarters, the factories in Ikebukuro, Sakai and Takada were destroyed in World War II, the headquarters were relocated to Takada, the factory in Takada was rebuilt
1946: Construction of the plant in Kamagiishi
1951: Guronsan, a drug to detoxify and restore liver function, is launched
1952: Varsan , a perspiration insecticide , is launched
1955: Chugai became a public company .
1956: The stock is listed on the Tokyo Stock Exchange
1957: Construction of the Ukima plant
1960: Establishment of a research center (Takada Research Laboratory, Tokyo)
1967: Foundation of Fukushima Kasai Co Ltd.
1961 – Developed patents for synthesis of vitamin A
1969: The name of Fukushima Kasai Co Ltd. is changed to Eiko Kasei Co Ltd . , after the merger of Fukushima Kasai Co Ltd. and Fukuma Kasau Co. Ltd.
1971: Construction of the factory in Fujieda
1975: Picibanil , a cancer drug, is launched
1982: Opening of a branch in New York
1986: Opening of a branch in London
1989: Acquisition of Gen-Probe Incorporated (USA)
1990: Epogin launched
1995 – Released acute promyelocytic sphere of leukemia drug treatment Vesanoid
1996 – Released anti-viral chemotherapeutic agent Hivid (HIV reverse transcriptase inhibitor)
1997 – Released HIV protease inhibitor Invirase
1999 – Released immunosuppressive agent Cellcept
2000 – Released antiemetic drug Kytril, developed to combat the side effects of chemotherapy
2001 – Produced anti-influenza virus Tamiflu (Roche)
2002: Start of the alliance with Roche
2003: Xeloda , a cancer drug, is launched
2005: Actemra launched
2007: Copegus , an antiviral, Avastin , a cancer drug, and Tarceva , a cancer drug launched
2011 – Produced Actemra, a human IL-6 receptor monoclonal antibody for rheumatoid arthritis
2014: Launch of Kadcyla , a cancer drug, Chugai Pharma China Co Ltd. founded
2015 – In March the company announced it would co-commercialise Athersys's stem cell therapy for ischemic strokes in Japan. The deal could yield upwards of US$205 million.^[3]
2016: Cooperation between Osaka University and Chugai
2018: Tecentriq , a cancer drug, is launched
2020 – FDA approved satralizumab (Enspryng) for treatment of the orphan disease neuromyelitis optica^[4]

References

^ Cortez, Michelle Fay; Matsuyama, Kanoko (25 August 2014). "Roche Said to Have Decided Against Bid for Rest of Chugai". Bloomberg.
^ "History of Chugai Pharmaceutical". 23 December 2015. Archived from the original on 1 November 2020. Retrieved 18 June 2019.
^ Staff (2 March 2015). "Chugai to Co-Develop Athersys' Cell Therapy in Japan in Up-to-$205M Partnership". Genetic Engineering & Biotechnology News (Paper, Vol 35, i 7, p. 12). Retrieved 11 June 2016.
^ "FDA Approves Treatment for Rare Disease Affecting Optic Nerves, Spinal Cord". U.S. Food and Drug Administration. 17 August 2020. Retrieved 18 August 2020.